Mesa Laboratories (MLAB) Upgraded to Hold by Zacks Investment Research

Zacks Investment Research upgraded shares of Mesa Laboratories (NASDAQ:MLAB) from a strong sell rating to a hold rating in a report issued on Tuesday.

According to Zacks, “MESA LABORATORIES, INC. designs, develops, acquires, manufactures and markets instruments and systems utilized in connection with industrial applications and hemodialysis therapy. “

Separately, TheStreet upgraded Mesa Laboratories from a c+ rating to a b rating in a research report on Monday, November 6th.

Mesa Laboratories (MLAB) traded up $0.82 on Tuesday, reaching $133.66. The company had a trading volume of 4,394 shares, compared to its average volume of 14,478. The stock has a market capitalization of $502.10, a price-to-earnings ratio of 48.25 and a beta of 0.42. Mesa Laboratories has a 12 month low of $113.57 and a 12 month high of $169.80. The company has a current ratio of 2.86, a quick ratio of 1.97 and a debt-to-equity ratio of 0.48.

Mesa Laboratories (NASDAQ:MLAB) last released its quarterly earnings results on Monday, November 6th. The medical instruments supplier reported $0.60 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.64 by ($0.04). The company had revenue of $22.95 million during the quarter, compared to analysts’ expectations of $25.50 million. Mesa Laboratories had a return on equity of 14.77% and a net margin of 11.48%. analysts predict that Mesa Laboratories will post 2.47 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 15th. Shareholders of record on Wednesday, February 28th will be given a dividend of $0.16 per share. The ex-dividend date is Tuesday, February 27th. This represents a $0.64 annualized dividend and a dividend yield of 0.48%. Mesa Laboratories’s dividend payout ratio (DPR) is presently 23.10%.

Several large investors have recently made changes to their positions in the business. PNC Financial Services Group Inc. boosted its position in shares of Mesa Laboratories by 2.3% during the second quarter. PNC Financial Services Group Inc. now owns 3,117 shares of the medical instruments supplier’s stock valued at $446,000 after buying an additional 71 shares during the period. The Manufacturers Life Insurance Company boosted its position in shares of Mesa Laboratories by 7.1% during the second quarter. The Manufacturers Life Insurance Company now owns 2,564 shares of the medical instruments supplier’s stock valued at $367,000 after buying an additional 169 shares during the period. Swiss National Bank boosted its position in shares of Mesa Laboratories by 9.6% during the second quarter. Swiss National Bank now owns 5,702 shares of the medical instruments supplier’s stock valued at $817,000 after buying an additional 500 shares during the period. Wells Fargo & Company MN boosted its position in shares of Mesa Laboratories by 19.9% during the second quarter. Wells Fargo & Company MN now owns 3,326 shares of the medical instruments supplier’s stock valued at $476,000 after buying an additional 553 shares during the period. Finally, Teachers Advisors LLC boosted its position in shares of Mesa Laboratories by 14.9% during the second quarter. Teachers Advisors LLC now owns 5,660 shares of the medical instruments supplier’s stock valued at $811,000 after buying an additional 733 shares during the period. Institutional investors and hedge funds own 69.79% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Mesa Laboratories (MLAB) Upgraded to Hold by Zacks Investment Research” was reported by Week Herald and is owned by of Week Herald. If you are viewing this article on another domain, it was illegally copied and republished in violation of international copyright legislation. The correct version of this article can be accessed at https://weekherald.com/2018/01/13/mesa-laboratories-mlab-upgraded-to-hold-by-zacks-investment-research.html.

About Mesa Laboratories

Mesa Laboratories, Inc is focused primarily on quality control products and services. The Company operates through four segments: Instruments, Continuous Monitoring, Biological Indicators and Cold Chain. The Instruments Division designs, manufactures and markets quality control instruments and disposable products.

Receive News & Ratings for Mesa Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesa Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply